Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.

ABSTRACT:

Background

Few studies report the effects of tamoxifen intake and the occurrence of de novo fatty liver and the deterioration of existing fatty liver. The aim of this study was to investigate the effects of tamoxifen on fatty change of liver over time and also the impact of fatty liver on the prognosis of patients with breast cancer.

Methods

This was a single-center, retrospective study of patients who were diagnosed with primary breast cancer from January 2007 to July 2017. 911 consecutive patients were classified into three groups according to treatment method: tamoxifen group, aromatase inhibitor (AI) group, and control group.

Results

Median treatment duration was 49 months (interquartile range, IQR; 32-58) and median observational period was 85 months (IQR; 50-118

SUBMITTER: Yoo JJ 

PROVIDER: S-EPMC7392315 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature